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CLINICAL GUIDELINES

Highlights of Clinical Practice Guideline for the Management
of Community-Acquired Pneumonia
2019 Update by the American Thoracic Society and Infectious
Diseases Society of America
Hongmei Wang, PharmD, PhD, BCPS,*† Molly Brong, PharmD,*
Shirley Pham, PharmD,*, and Diane Dreucean, PharmD†
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Abstract: Pneumonia is the leading cause of morbidity and mortality in
the United States. The American Thoracic Society and The Infectious Diseases Society of America recently published updated guidelines for the diagnosis and treatment of community-acquired pneumonia. Initial antibiotic
therapy should cover for Streptococcus pneumoniae, Haemophilus influenzae,
and other gram-negative bacilli. Patients who have risk factors for the development of antibiotic resistant pathogens, such as methicillin-resistant
Staphylococcus aureus and Pseudomonas aeruginosa should have appropriate empiric coverage for these pathogens. The recommended duration of
treatment of community-acquired pneumonia is a minimum of 5 days in
conjunction with clinical improvement, which has remained consistent
from previous guidelines.
Key Words: pneumonia, community-acquired pneumonia, guideline,
diagnosis
(Infect Dis Clin Pract 2020;28: 188–190)

ADDITIONAL TESTS

A

n update of the American Thoracic Society (ATS) and Infectious Diseases Society of America (IDSA) clinical guideline
for management and prevention of community-acquired pneumonia
(CAP) was published in print form (also available at http://www.
idsociety.org). These guidelines are an update of the guidelines
published by ATS/IDSA in 2019.1
The following are selected recommendations from this new
guideline regarding diagnosis and treatment of CAP. Comments
by the authors of this review are in italics.

DIAGNOSIS
• Obtaining a blood culture, sputum culture, or sputum Gram stain
routinely in adults treated in outpatient settings is not recommended.
• Pretreatment blood culture, sputum culture and Gram stain of respiratory secretion are recommended in adults with the following:
–Classified as having severe CAP
–Receiving empiric therapy for methicillin-resistant Staphylococcus
aureus (MRSA) or Pseudomonas aeruginosa
–Previous documented infection of MRSA or P. aeruginosa
–Hospitalized and received parenteral antibiotics in the last 90 days

Diagnosis is assessed based on patient's clinical presentation
of signs and symptoms, as well as diagnostic imaging. Typical signs
and symptoms of pneumonia include couth with or without
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sputum production, shortness of breath, chest pain, tachypnea,
and increased work of breathing. Systemic signs can include fever,
chills, malaise, fatigue, and elevated white blood cell counts. A diagnosis is confirmed when the chest x-ray shows infiltrates and
clinical presentation matches.
The decision to obtain cultures should be determined on the
basis of clinical presentation, local etiological considerations, and
local antimicrobial stewardship processes. Historically, sputum cultures
and Gram stains had poor positive predictive values. Routinely obtaining
cultures have led to false-positive results from contaminants leading to
inappropriate antibiotic use and increased hospital length of stay. In severe CAP, however, delay in covering multidrug resistant organisms
may lead to worse patient outcomes. Therefore, the benefit of obtaining
early cultures is crucial for deescalation in this patient population.

• The routine uses of urinary antigens Streptococcus pneumoniae
or Legionella are not recommended. Exceptions to this recommendation include adults with severe CAP, patients who may
have been exposed to an area of recent outbreak, or CAP associated with recent travel.
• If a patient presents with flu-like symptoms or illness, clinical
judgments should warrant testing for influenza.
• Procalcitonin should not be used alone as a clinical predictor of
initiation antibiotics.
• The Pneumonia Severity Index (PSI) is not recommended over
the tool based on confusion, urea level, respiratory rate, blood
pressure, and age greater or equal to 65 to determine if patients
warrant hospitalization.

The rationale behind the use of urinary antigens comes from
randomized trials that have demonstrated poor negative predictive
value of urinary antigen testing2; however, a handful of large observational studies have shown that urinary antigen testing has been
associated with a reduction in mortality.3 Overall, the basis behind
the recommendation to avoid unnecessary testing is appropriate
given the current landscape of available literature.
In the past, some investigators have previously suggested that
certain levels of procalcitonin indicate presence of bacterial infections.4 The guidelines now recommend that procalcitonin should
not be used alone as a clinical predictor of initiation antibiotics based
on recent literature that failed to identify a procalcitonin threshold
to distinguish between bacterial and viral pathogens.5
The PSI and CURB-65 were developed as validated clinical
prediction rules for prognosis of CAP in immunocompetent patients.
The PSI is now recommended over the CURB-65 to determine
if patients warrant hospitalization.6 Consistent with previous
guidelines, clinical prediction tools should be used in combination
with clinical judgments.
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CLASSIFICATION
• The term health care–associated pneumonia (HCAP) should
be eliminated.

The 2005 ATS/IDSA guidelines for the management of hospitalacquired and ventilator associated pneumonia defined a subset of
pneumonia, which was termed HCAP.7 It attempted to stratify patients with potential risk factors for multidrug-resistant infections.
These previous risk factors included patients who reside in a nursing home or long-term care facility, hospitalization for at least 2 days
in the last 90 days, receiving home infusion therapy, chronic dialysis, home wound care, or a caregiver who is known to have an
antibiotic-resistant pathogen. Many studies have recently demonstrated that risk factors used to define HCAP do not correlate with
higher rates of antimicrobial-resistant pathogens.8 The two consistently proven and strongest risk factors associated with MRSA
and P. aeruginosa infections are a previous hospitalization (within
the last 90 days) in which the patient received treatment with parenteral antibiotics and previous confirmed infection with either
MRSA or P. aeruginosa. Recent literature has outlined deficiencies in the positive predictive value of the current HCAP criteria.9
Patients should be stratified based on their individual risk for
MRSA or P. aeruginosa and treated accordingly.

TREATMENT
• Outpatient empiric treatment
–Macrolide monotherapy should only be used in geographical
areas with proven pneumococcal resistance of less than 25%.
–Amoxicillin or doxycycline should be used in patients
without comorbidities.
–Macrolide in combination with Augmentin or a cephalosporin
or respiratory fluoroquinolone monotherapy should be used in
patients with comorbidities.
• Inpatient empiric treatment without MRSA and P. aeruginosa
risk factors
–Combination therapy with a β-lactam and a macrolide
is recommended.
–Monotherapy with a respiratory fluoroquinolone is recommended.
–Patients who have a contraindication to both macrolides and
fluoroquinolones should receive combination therapy with a
β-lactam and doxycycline.
• Inpatient treatment with MRSA and P. aeruginosa risk factors
–Empiric therapy for MRSA includes vancomycin or linezolid.
–Empiric therapy for P. aeruginosa includes piperacillin-tazobactam,
cefepime, ceftazidime, aztreonam, meropenem, and imipenem.
• Influenza
–Oseltamivir is recommended for adults with CAP to test positive for influenza in both the inpatient and outpatient setting.
–Treatment within 2 days of symptom onset or hospitalization
may result in the best outcomes.10
–In patients with a positive influenza test, no evidence of a bacterial pathogen (including a low procalcitonin level), and early clinical stability, early discontinuation of antibiotics should be considered.

In the 2007 guidelines, nonsevere CAP patients without comorbidities qualified for macrolide monotherapy as first line treatment.11
Since then, the prevalence of resistant strains of S. pneumoniae
has increased. It is currently estimated that macrolide resistance
is greater than 25% in most areas of the United States.12
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Treatment within 2 days of symptom onset or hospitalization
may result in the best outcomes.10 The use of anti-influenza agents
in the outpatient setting reduces duration of symptoms and likelihood
of complications in patients with influenza. Anti-influenza agents
have shown to reduce mortality risk in the inpatient setting. Although
it is most beneficial to start therapy within 2 days of symptom onset, studies also support starting at a later time to prevent the risk
of viral shedding and potential transmission to other patients.13
In adults with CAP who test positive for influenza, standard
antibacterial treatment should be initiated. Bacterial infections can
occur concomitantly with an influenza infection. Staphylococcus
aureus is the most common superimposed bacterial infection associated with influenza pneumonia. In patients with a positive influenza test, no evidence of a bacterial pathogen, and early clinical
stability, early discontinuation of antibiotics should be considered.

DURATION OF THERAPY
• Duration of therapy should be based on clinical improvement
with a minimum of at least 5 days treatment.
• Longer courses of antibiotic therapy are recommended for the
following:
–Pneumonia complicated by meningitis, endocarditis, and other
deep-seated infection.
–Infection with other, less-common pathogens (eg, Burkholderia
pseudomallei, Mycobacterium tuberculosis, or endemic fungi)
–MRSA or P. aeruginosa infections (total antibiotic duration
of 7 days)

Validated measures such as heart rate, respiratory rate, blood
pressure, oxygen saturation, temperature, appetite, and normal
mentation should be used to determine clinical improvement. Antibiotic therapy should be continued until the patient achieves stability for at least 5 days. Most patients will achieve clinical stability
within the first 2 to 3 days; therefore, a total duration of 5 days is
appropriate. Procalcitonin levels are useful in settings where the
hospital length of stay exceeds 5 to 7 days. Failure to achieve clinical stability within 5 days is associated with higher mortality and
worse clinical outcomes.14 This should prompt the assessment for
a pathogen resistant to the current therapy, a complication of
pneumonia, or another source of infection.
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